For further analysis, we determined the potential roles of the KRAS/MMP7/CD44 oncogenes as factors that influence high diagnostic efficacy in CRC patients; therefore, we explored a ROC analysis based on the TCGA database, on patients’ responses to chemotherapy treatment based on RECIST criteria, and results showed that patients with increased levels of these genes responded poorly to treatment (Figure 3). This evidence concerns the gene KRAS and colorectal carcinoma.